In Pancreatic Cancer, Blood Neutrophil-Lymphocyte Ratio Predicts Survival
the Cancer Therapy Advisor take:
Baseline and post-chemotherapy neutrophil-lymphocyte ratio (NLR) change are potential biomarkers for overall survival in patients with advanced pancreatic cancer undergoing chemotherapy, according to a study published in the Annals of Surgical Oncology.
Researchers at the Fudan University Shanghai Cancer Center in China retrospectively examined 403 patients who had undergone chemotherapy for advanced pancreatic adenocarcinoma from 2002 to 2013. They wanted to determine the prognostic role of NLR in these patients.
The researchers performed univariate and multivariate analyses in order to identify clinicopathological predictors of overall survival that included baseline NLR and post-chemotherapy NLR.
They found that both baseline NLR and post-chemotherapy NLR change were independent prognostic factors in overall survival.
NLR of 3.1 or greater before chemotherapy as well as NLR post-chemotherapy change were both significantly associated with distant metastasis, serum CA19-9 levels and serum albumin levels.
NLR change is a potential biomarker for survival in advanced pancreatic cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol